Exagamglogene autotemcel (Casgevy)
Mechanism of action
Gene therapy
Diseases for which it is established
History of changes in FDA indication
- 2023-12-08: Approved for the treatment of sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs). (Based on CLIMB SCD-121)
- 2024-01-16: Approved for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. (Based on CLIMB THAL-111)
Also known as
- Generic name: exa-cel
- Brand name: Casgevy